Plain-English translation of NCT07024602 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called ASC50 to see if it is safe and how the body processes it. The trial involves healthy volunteers and people with mild to moderate plaque psoriasis. Researchers will test different doses of this medication, starting low and increasing gradually, to find the right balance between safety and benefit.
Plaque psoriasis is a chronic skin condition that causes itching, pain, and visible plaques. Current treatments don't work well for everyone, and this medication is being explored as a potentially new option to help manage the condition.
Participants will either receive a single dose of the medication followed by observation, or take the medication daily for 28 days. Some participants will receive the actual medication while others receive a placebo (inactive pill), and neither they nor the researchers will know which they received. Throughout the study, participants will have blood samples taken, be monitored for side effects, and complete follow-up visits to track how their body handles the medication.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Ascletis Pharma (China) Co., Limited
Enrollment target
~55 participants
Started
June 2025
Primary completion
July 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in September 2026.